MannKind Corporation to Ring the Nasdaq Stock Market Opening Bell
MannKind Corporation (Nasdaq: MNKD) announced that CEO Michael Castagna will ring the opening bell at Nasdaq on May 23, 2022, at 9:30 am ET. The ceremony is part of a promotional event to highlight the company's focus on inhaled therapeutic products for endocrine and orphan lung diseases. MannKind's flagship product, Afrezza, is the only FDA-approved inhaled ultra-rapid acting mealtime insulin in the U.S. and is also available in Brazil through its partner, Biomm SA. This event reflects the company’s commitment to bringing innovative treatments to market.
- MannKind's CEO will ring the Nasdaq opening bell, enhancing visibility.
- Afrezza is the only inhaled ultra-rapid acting mealtime insulin approved in the U.S.
- None.
WESTLAKE VILLAGE, Calif. and DANBURY, Conn., May 19, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that its Chief Executive Officer, Michael Castagna, PharmD, will ring the opening bell at the Nasdaq stock exchange on Monday, May 23, 2022 at 9:30 am ET at the Nasdaq MarketSite at Times Square.
The ceremony will begin at approximately 9:15 am ET and can be viewed live from the Events & Presentations section of the Company’s website at https://investors.mannkindcorp.com/events-and-presentations.
About MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company’s first FDA-approved product and the only inhaled ultra rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide. Afrezza is also available by prescription in Brazil, where it is commercialized by the Company’s partner, Biomm SA. MannKind was established in 1991, and is located in Danbury, Conn., and Westlake Village, Calif. The Company also employs field sales and medical representatives across the U.S. Please visit mannkindcorp.com to learn more.
MANNKIND CONTACTS:
Christie Iacangelo, Corporate Communications
(818) 292-3500
Email: media@mannkindcorp.com
Rose Alinaya, Investor Relations
(818) 661-5000
Email: ir@mannkindcorp.com
FAQ
When will MannKind ring the opening bell at Nasdaq?
What is the significance of MannKind's CEO ringing the opening bell?
What is Afrezza and its relevance to MannKind?
Which stock exchange is MannKind listed on?
